Biotech | December 24, 2021
Lecanemab granted Fast Track designation by the U.S. FDA
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Alzheimer's disease is a serious, progressive and devastating disease with few treatment options
Philips’s CavaClear is intended to safely ablate tissue to remove embedded IVC filters
Trastuzumab is monoclonal antibody used to treat human epidermal growth factor receptor 2 positive (HER2+) breast cancer and metastatic gastric cancers
Given as few as six times per year and demonstrated superior efficacy to a daily oral PrEP option (FTC/TDF tablets) in reducing the risk of HIV acquisition
While continuing to offer its current breadth of genomic services, Biogazelle will become CellCarta's Center of Excellence for the development of complex genomic biomarker assays
The company will provide recyclability services to brands with a final goal to help them move to fully recyclable packaging
Expanded EUA includes both treatment of patients with Covid-19 and post-exposure prophylaxis (PEP) in high-risk pediatric and infant patients
Lupin had earlier received the U.S. FDA acceptance of the Biologics License Application (BLA) for Its proposed biosimilar
MJ will be paid a one-time lumpsum licence fee of Rs 15 crore
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
Subscribe To Our Newsletter & Stay Updated
